Listen on the go
CORRECT!
Next question
touchHAEMATOLOGY touchHAEMATOLOGY
    • FILTER YOUR SEARCH
    Content Type:
    Speciality:
    More Specialities
    Conference:
    More Conferences

    • Genetic Blood Disorders

    Genetic Blood Disorders Content

    COVID-19, Anaemia, Leukaemia, Myeloproliferative Disorders, Haematological Malignancies, Myelodysplastic Syndrome, Paediatric Haematology, Rare Diseases, Thrombocytopenia, White Blood Cell Disorders, Genetic Blood Disorders, Amyloidosis, Autoimmune Blood Disorders, Blood and Bone Marrow Transplantation, Bloodstream Infections, Haemostatic Disorders, Lymphoma, Maternal-foetal Medicine, Myeloma, Platelet Disorders, Policy, Transfusion Medicine
    What’s on the horizon for continuing medical education? Insights from touchIME

    In this episode, we explore the future of continuing medical education (CME) with the team behind touchIME. Hannah Fisher and Matthew Goodwin share insights into global and US trends, the importance of patient inclusivity and how educational outcomes are evolving to better measure the direct impact of learning on clinical practice and patient care.

    COVID-19, Anaemia, Leukaemia, Myeloproliferative Disorders, Haematological Malignancies, Myelodysplastic Syndrome, Paediatric Haematology, Rare Diseases, Thrombocytopenia, White Blood Cell Disorders, Genetic Blood Disorders, Amyloidosis, Autoimmune Blood Disorders, Blood and Bone Marrow Transplantation, Bloodstream Infections, Haemostatic Disorders, Lymphoma, Maternal-foetal Medicine, Myeloma, Platelet Disorders, Policy, Transfusion Medicine
    Supporting haematology patient care: Insights from the Haematology Nurses and Healthcare Professionals Group

    Nurses account for the largest group of professionals in the healthcare system and there are an estimated 29 million nurses worldwide (WHO, 2024). Nursing practice needs to be dynamic in order to respond to the changing needs of an aging population and the increasing incidence of chronic diseases (WHO, 2022; Hacker, 2024). Within the haematology […]

    Genetic Blood Disorders
    blood anaemia
    New hope for sickle cell treatment

    Researchers at Vanderbilt University Medical Center (VUMC) have highlighted promising results from a phase II clinical trial for a new treatment for sickle cell disease (SCD). Published in Blood, the study aimed to achieve an 80% two-year event-free survival rate following a specific bone marrow transplant (BMT) method. The international trial, led by Dr DeBaun and Dr Adetola Kassim, involved 32 children and 38 adults from five countries.

    Paediatric Haematology, Haematological Malignancies, Genetic Blood Disorders
    Watch Time: 48 mins
    touchMDT
    Recognizing and managing HLH in the critical care setting: Best practice for the multidisciplinary team
    CE/CME ACCREDITED Prof. Michael Jordan, Dr Kate Kernan, Dr Eric Gars, Prof. Rob MacLaren Translations available:

    Multidisciplinary experts discuss the diagnosis and management of haemophagocytic lymphohistiocytosis (HLH)

    Learning objectives
    Learning Objectives
    • Describe the characteristic clinical and laboratory findings of HLH, and the confirmatory diagnostic tests
    • Explain the identification of predisposing conditions and acute triggers associated with HLH and how these affect treatment selection and monitoring
    • Implement effective multidisciplinary strategies for the diagnosis, monitoring and management of HLH in the critical care setting
    Genetic Blood Disorders
    Watch Time: 39 mins
    touchPANEL DISCUSSION
    Contemporary insights on the management of sickle cell disease: Focus on complications and recent advances in therapy
    CE/CME ACCREDITED Prof. Biree Andemariam, Prof. Modupe Idowu, Prof. Mark C Walters

    Three experts discuss the management of complications of sickle cell disease, as well as recent advances in therapy.

    Learning objectives
    Learning Objectives
    • Summarize the various manifestations and multiple complications of SCD
    • Appraise the practical considerations for the multidisciplinary management of SCD complications
    • Interpret the clinical data for established and recently approved therapies for SCD and apply them to clinical practice
    Genetic Blood Disorders
    Watch Time: 37 mins
    touchPANEL DISCUSSION
    Navigating pyruvate kinase deficiency today: How can the disease burden and unmet treatment needs be addressed?
    CE/CME ACCREDITED Dr Rachael Grace, Dr Hanny Al-Samkari, Dr Ami J Shah

    Three experts discuss the burden and clinical presentation of pyruvate kinase deficiency, as well as current and emerging therapeutic strategies.

    Learning objectives
    Learning Objectives
    • Recognize the signs and symptoms of PK deficiency and the burden of disease in affected patients
    • Evaluate established therapeutic strategies for PK deficiency and identify remaining unmet treatment needs
    • Describe novel and emerging therapeutic strategies for PK deficiency and how they may address current unmet needs
    Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72
    Close Popup